SG11201408536WA - METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF - Google Patents
METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOFInfo
- Publication number
- SG11201408536WA SG11201408536WA SG11201408536WA SG11201408536WA SG11201408536WA SG 11201408536W A SG11201408536W A SG 11201408536WA SG 11201408536W A SG11201408536W A SG 11201408536WA SG 11201408536W A SG11201408536W A SG 11201408536WA SG 11201408536W A SG11201408536W A SG 11201408536WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- penzberg
- pct
- fusion
- denotes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179025 | 2012-08-02 | ||
| PCT/EP2013/066065 WO2014020056A1 (en) | 2012-08-02 | 2013-07-31 | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408536WA true SG11201408536WA (en) | 2015-01-29 |
Family
ID=48986096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408536WA SG11201408536WA (en) | 2012-08-02 | 2013-07-31 | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10011644B2 (zh) |
| EP (1) | EP2880170B1 (zh) |
| JP (1) | JP6307077B2 (zh) |
| KR (1) | KR20150038511A (zh) |
| CN (1) | CN104508132B (zh) |
| BR (1) | BR112015002263A2 (zh) |
| CA (1) | CA2876096A1 (zh) |
| DK (1) | DK2880170T3 (zh) |
| ES (1) | ES2602030T3 (zh) |
| HK (1) | HK1208881A1 (zh) |
| HU (1) | HUE029634T2 (zh) |
| MX (1) | MX2015000681A (zh) |
| PL (1) | PL2880170T3 (zh) |
| RU (1) | RU2630659C2 (zh) |
| SG (1) | SG11201408536WA (zh) |
| SI (1) | SI2880170T1 (zh) |
| WO (1) | WO2014020056A1 (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2746052T3 (es) | 2011-06-28 | 2020-03-04 | Inhibrx Lp | Polipéptidos de fusión de serpina y métodos de uso de los mismos |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| IL308589A (en) * | 2014-10-27 | 2024-01-01 | Inhibrx Inc | Serpin-fused polypeptides and methods of using them |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| KR20170127015A (ko) | 2015-03-13 | 2017-11-20 | 유니버시티 오브 매릴랜드, 발티모어 | 만능항체 매개 바이오센서 |
| EP3356829A4 (en) * | 2015-10-02 | 2019-02-27 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | BINDING ASSAY AND METHOD OF SURVEYING ANTIBODY FUNCTION WITH FC BINDING MULTIMERS |
| JP6987424B2 (ja) | 2016-05-11 | 2022-01-05 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを洗浄および／または消毒する方法 |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP2019527537A (ja) * | 2016-06-07 | 2019-10-03 | マックス−デルブリュック−セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ−ゲマインシャフト | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ−ｔ細胞 |
| AU2017310163B2 (en) | 2016-08-10 | 2021-09-09 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
| KR20210005169A (ko) | 2018-04-25 | 2021-01-13 | 프로메테우스 바이오사이언시즈, 인크. | 최적화된 항tl1a 항체 |
| CN113286808A (zh) | 2018-10-23 | 2021-08-20 | 蜻蜓疗法股份有限公司 | 异二聚体Fc融合蛋白 |
| SG11202103568PA (en) * | 2018-10-23 | 2021-05-28 | Magenta Therapeutics Inc | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| EP4048309A4 (en) | 2019-10-24 | 2024-02-21 | Prometheus Biosciences Inc | HUMANIZED ANTIBODIES AGAINST TNF-LIKE LIGAND 1A (TL1A) AND THEIR USES |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5623053A (en) * | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| CN1341121A (zh) * | 1999-01-07 | 2002-03-20 | 利思进药品公司 | 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU782496B2 (en) | 1999-07-13 | 2005-08-04 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
| WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| BRPI0406724A (pt) * | 2003-01-13 | 2005-12-20 | Macrogenics Inc | Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7718363B2 (en) * | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2010516769A (ja) * | 2007-01-23 | 2010-05-20 | ザイモジェネティクス， インコーポレイテッド | 炎症を軽減するための可溶性ＦｃγＲＩＡ |
| US8658766B2 (en) | 2008-06-27 | 2014-02-25 | Zymogenetics, Inc. | Soluble hybrid Fcγ receptors and related methods |
| EP2365979A2 (en) * | 2008-10-22 | 2011-09-21 | Biogen Idec MA Inc. | Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
-
2013
- 2013-07-31 BR BR112015002263A patent/BR112015002263A2/pt not_active IP Right Cessation
- 2013-07-31 SG SG11201408536WA patent/SG11201408536WA/en unknown
- 2013-07-31 ES ES13750004.7T patent/ES2602030T3/es active Active
- 2013-07-31 RU RU2015104625A patent/RU2630659C2/ru not_active IP Right Cessation
- 2013-07-31 WO PCT/EP2013/066065 patent/WO2014020056A1/en active Application Filing
- 2013-07-31 HU HUE13750004A patent/HUE029634T2/en unknown
- 2013-07-31 CN CN201380040154.7A patent/CN104508132B/zh active Active
- 2013-07-31 PL PL13750004T patent/PL2880170T3/pl unknown
- 2013-07-31 CA CA2876096A patent/CA2876096A1/en not_active Abandoned
- 2013-07-31 SI SI201330354A patent/SI2880170T1/sl unknown
- 2013-07-31 JP JP2015524773A patent/JP6307077B2/ja active Active
- 2013-07-31 DK DK13750004.7T patent/DK2880170T3/en active
- 2013-07-31 MX MX2015000681A patent/MX2015000681A/es unknown
- 2013-07-31 EP EP13750004.7A patent/EP2880170B1/en active Active
- 2013-07-31 KR KR20157005311A patent/KR20150038511A/ko not_active Application Discontinuation
-
2015
- 2015-02-02 US US14/611,645 patent/US10011644B2/en active Active
- 2015-09-29 HK HK15109569.5A patent/HK1208881A1/zh unknown
-
2018
- 2018-06-04 US US15/996,846 patent/US10093714B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1208881A1 (zh) | 2016-03-18 |
| US10011644B2 (en) | 2018-07-03 |
| US20150140683A1 (en) | 2015-05-21 |
| RU2015104625A (ru) | 2016-09-20 |
| US20180265564A1 (en) | 2018-09-20 |
| MX2015000681A (es) | 2015-04-10 |
| CN104508132A (zh) | 2015-04-08 |
| US10093714B1 (en) | 2018-10-09 |
| WO2014020056A1 (en) | 2014-02-06 |
| BR112015002263A2 (pt) | 2017-12-12 |
| HUE029634T2 (en) | 2017-03-28 |
| EP2880170A1 (en) | 2015-06-10 |
| CN104508132B (zh) | 2017-09-15 |
| SI2880170T1 (sl) | 2016-12-30 |
| DK2880170T3 (en) | 2016-10-24 |
| EP2880170B1 (en) | 2016-08-24 |
| RU2630659C2 (ru) | 2017-09-11 |
| CA2876096A1 (en) | 2014-02-06 |
| JP2015526429A (ja) | 2015-09-10 |
| KR20150038511A (ko) | 2015-04-08 |
| PL2880170T3 (pl) | 2017-02-28 |
| ES2602030T3 (es) | 2017-02-17 |
| JP6307077B2 (ja) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201808678QA (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201408261UA (en) | Syringe | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201407483YA (en) | Compositions and methods for modulating smn gene family expression | |
| SG11201407233RA (en) | Ethylene oligomerization process | |
| SG11201407774XA (en) | Conversion of biomass | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201808476SA (en) | Recycling of polymer matrix composite | |
| SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions |